Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coulter Bexxar

Executive Summary

New NDA filing for the iodine I 131 tositumomab product is no longer expected by mid-October, CEO Michael Bigham told analysts Sept. 28. The Aug. 27 "refuse-to-file" letter from FDA required Coulter to reformat selected data sets, reorganize certain analyses and provide archival images. Bigham said a meeting the company requested with FDA will not take place until mid-October, delaying the resubmission. Co-marketing partner SmithKline Beecham has indicated that it is helping Coulter with the submission (1"The Pink Sheet" Sept. 27, p. 22)

You may also be interested in...



Corixa Acquisition Of Coulter Gives Company Bexxar, Pending At FDA

Corixa's acquisition of Coulter will give the company its most advanced late-stage clinical product, the non-Hodgkin's lymphoma therapy Bexxar.

Corixa Acquisition Of Coulter Gives Company Bexxar, Pending At FDA

Corixa's acquisition of Coulter will give the company its most advanced late-stage clinical product, the non-Hodgkin's lymphoma therapy Bexxar.

Zevalin/Rituxan Has 80% Response Rate In Non-Hodgkin's Lymphoma Patients

Idec's mouse monoclonal antibody Zevalin in combination with the firm's Rituxan produced an 80% overall response rate in patients with relapsed B-cell non-Hodgkin's lymphoma in an interim analysis of Phase III data presented in a poster May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.

Related Content

UsernamePublicRestriction

Register

PS034950

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel